-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41

Benzinga·05/02/2025 22:54:47
Listen to the news
UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and lowers the price target from $47 to $41.